Activities of SYK and PLCĪ³2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib Academic Article uri icon

Overview

MeSH Major

  • Apoptosis
  • Intracellular Signaling Peptides and Proteins
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Phospholipase C gamma
  • Protein-Tyrosine Kinases
  • Pyrimidines
  • Thiazoles

abstract

  • Thus, SYK inhibition predicts cellular response to dasatinib. SYK, together with phospholipase Cgamma2, may serve as potential biomarkers to predict dasatinib therapeutic response in patients. From the pathogenic perspective, our study suggests the existence of alternative mechanisms or pathways that activate SYK, independent of SRC kinase activities. The study further implicates that SYK might serve as a more effective therapeutic target in CLL treatment.

publication date

  • January 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-09-1519

PubMed ID

  • 20068106

Additional Document Info

start page

  • 587

end page

  • 99

volume

  • 16

number

  • 2